ReviewMalaria journal2025
Larviciding for malaria control and elimination in Africa.
Review in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- The potential of Clonostachys rosea as a biolarvicide against Anopheles gambiae.Journal of invertebrate pathology · 2026Article
- Impact of Insecticide-Treated Nets onTropical medicine and infectious disease · 2026Article
- Article
- Molecular xenomonitoring for identifying Plasmodium parasites and blood meal sources of mosquitoes in malaria endemic villages adjacent to the southern Rift Valley Lakes, South Ethiopia.Scientific reports · 2026Article
- Sublethal Pyriproxyfen Exposure AltersInsects · 2026Article
- The Evolving Landscape of Malaria Prevention Strategies: A Review of Recent Developments.Pathogens (Basel, Switzerland) · 2026Review
- Modelling the impact of mosquito bed net utilization on malaria transmission and evolution of pyrethroid resistance.PloS one · 2026Article
- Semi-field evaluation of efficacy and residual activity of a microencapsulated pyriproxyfen formulation onMalariaWorld journal · 2026Article
- Outdoor biting by malaria vectors: what are the options for intervention?Malaria journal · 2025Review
- A large-scale mosquito larviciding in Tanga Region, Tanzania, reduced mosquito densities to varying degrees across malaria transmission risk strata.Scientific reports · 2025Article
- A costing analysis of an intermittent biolarviciding intervention with limited epidemiological effect in Tanga Region, Tanzania.Malaria journal · 2025Article
- Large-scale intermittent larviciding intervention and associations with key malaria epidemiological parameters in Tanga Region, Tanzania.Malaria journal · 2025Article
- Building resilience against the growing threat of arboviruses: a scoping review of Aedes vector surveillance, control strategies and insecticide resistance in Africa.Parasites & vectors · 2025Article
- Malaria-anemia comorbidity and its determinants among pregnant women in high- and moderate-malaria-risk countries in Sub-Saharan Africa.Infectious diseases of poverty · 2025Article
- Heterogeneous impacts for malaria control from larviciding across villages and considerations for monitoring and evaluation.PLoS pathogens · 2025Article
- Anopheles arabiensis larval habitats characterization and Anopheles species diversity in water bodies from Jozini, KwaZulu-Natal Province.Malaria journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundGlobal progress toward malaria elimination and eradication goals has stagnated in recent years, with many African countries reporting increases in malaria morbidity and mortality. Insecticide-treated nets and indoor residual spraying are effective, but the emergence and increased intensity of insecticide resistance and the challenge of outdoor transmission are undermining their impact. New tools are needed to get back on track towards global targets. This Perspective explores the major challenges hindering wider-scale implementation of larviciding in Africa and identifies potential solutions and opportunities to overcome these barriers. LARVICIDING IN AFRICA: OVERVIEW, CHALLENGES, AND SOLUTIONS: Larviciding is a valuable vector control tool with strong potential for regional scale-up. There is considerable evidence of its effectiveness, and the World Health Organization (WHO) recommends it as a supplemental intervention. However, malaria programmes hoping to implement larviciding face significant barriers, including (1) poor global technical, policy, and funding support; (2) fragmented implementation and experience; (3) high complexity of delivery and impact evaluation; and (4) limited access to the full range of WHO prequalified larvicide products. Strategic barriers related to global policy and donor hesitancy can be overcome through a coordinated demonstration of cost-effectiveness. Technological advancements and strengthened operational capacity have already overcome technical barriers related to larvicide delivery, targeting, coverage, and evaluation. Developing a Community of Practice platform for larviciding has strong potential to consolidate efforts, addressing the challenge of fragmented implementation and experience. Such a platform can serve as a resource center for African malaria programmes, collating and disseminating technical guidance, facilitating the exchange of best practices, and aiding malaria programmes and partners in designing and evaluating larviciding projects.
conclusionThe global shift toward targeted and adaptive interventions enables the incorporation of larviciding into an expanded vector control toolbox. As more African countries implement larvicide programmes, establishing a regional Community of Practice platform for exchanging experiences and best practices is necessary to strengthen the evidence base for cost-effective implementation, advocate for support, and inform policy recommendations, thus supporting Africa's progress toward malaria elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.